Free Trial

Aytu BioPharma Q4 2024 Earnings Report

Aytu BioPharma logo
$1.03 -0.04 (-3.74%)
As of 04/4/2025 04:00 PM Eastern

Aytu BioPharma EPS Results

Actual EPS
-$0.82
Consensus EPS
-$0.45
Beat/Miss
Missed by -$0.37
One Year Ago EPS
N/A

Aytu BioPharma Revenue Results

Actual Revenue
$17.98 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aytu BioPharma Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Remove Ads

Aytu BioPharma Earnings Headlines

Feds Just Admitted It—They Can Take Your Cash
The Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money isn't legally yours. Now, think your savings are safe? Think again.
See More Aytu BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aytu BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aytu BioPharma and other key companies, straight to your email.

About Aytu BioPharma

Aytu BioPharma (NASDAQ:AYTU) is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

View Aytu BioPharma Profile

More Earnings Resources from MarketBeat